Switch to tacrolimus for cyclosporine-induced gynecomastia in liver transplant recipients

Transplant Proc. 2005 Jul-Aug;37(6):2632-3. doi: 10.1016/j.transproceed.2005.06.019.

Abstract

We report herein on two male liver transplant (LT) recipients who presented with cyclosporine (CsA)-related gynecomastia 6 and 10 months after transplantation. The clinical workup showed increased luteinizing hormone (LH), associated with a slight reduction in testosterone blood levels in one patient and increased prolactin levels in the other. After excluding concomitant primary endocrine and/or malignant disease, conversion to tacrolimus (TAC) was performed resulting in clinical improvement of gynecomastia and return of hormone blood levels to normal range within 3 months. Our report confirms a putative role of CsA in post-LT gynecomastia, reversible however upon conversion to TAC.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Hepatocellular / surgery
  • Cholangitis, Sclerosing / surgery
  • Cyclosporine / adverse effects*
  • Gynecomastia / chemically induced*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Liver Neoplasms / surgery
  • Liver Transplantation / immunology*
  • Luteinizing Hormone / blood
  • Male
  • Middle Aged
  • Postoperative Complications / etiology
  • Prolactin / blood
  • Tacrolimus / therapeutic use*
  • Testosterone / blood

Substances

  • Immunosuppressive Agents
  • Testosterone
  • Cyclosporine
  • Prolactin
  • Luteinizing Hormone
  • Tacrolimus